NAV
$57.86
AUM
$241.6M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.87
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +7.08% | +2.34% | +4.21% | +16.20% | +14.80% | +7.33% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | AZN.L | AstraZeneca PLC | 1.52% |
| 2 | HSBA.L | HSBC Holdings PLC | 1.41% |
| 3 | NOVN.SW | Novartis AG Registered Shares | 1.36% |
| 4 | NESN.SW | Nestle SA | 1.30% |
| 5 | SIE.DE | Siemens AG | 1.22% |
| 6 | 6501.T | Hitachi Ltd | 1.19% |
| 7 | SU.PA | Schneider Electric SE | 1.11% |
| 8 | 1299.HK | AIA Group Ltd | 1.06% |
The fund seeks to outperform the price and yield performance of the MSCI World ex USA Index before including Fund expenses, while optimizing for LCETR scores criteria based on proprietary BFA research. The Advisor selects portfolio securities that are components of the index. The index measures the performance of large- and mid-capitalization stocks across global developed market countries, excluding the U.S.
Inception Date: 2021-04-06